GlassScriptPhysician profile
Ayedh K A Alamri
NPI 1124625124
$3,093.86
in general payments reported to CMS, 2019-2025
22 companies · $1,215 in 2025
The $1,215 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $109 · 2022: $151 · 2023: $450 · 2024: $1,169 · 2025: $1,215.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,833.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $467.25 | 2023-2025 | |
| Amgen INC. | $331.94 | 2023-2025 | Repatha, Repatha |
| Abiomed | $284.82 | 2025 | |
| United Therapeutics Corporation | $232.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $223.24 | 2023-2025 | Wainua, Farxiga, Lokelma |
| Actelion Pharmaceuticals US, INC. | $168.48 | 2024-2025 | Opsumit, Uptravi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $166.15 | 2024-2025 | Jardiance |
| Alnylam Pharmaceuticals INC. | $155.56 | 2023-2025 | Onpattro, Amvuttra |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $146.10 | 2023-2025 | Lifevest |
| Penumbra, INC. | $143.00 | 2025 | Indigo System |
| Angiodynamics, INC. | $113.59 | 2024 | Alphavac |
| Bayer Healthcare Pharmaceuticals INC. | $110.91 | 2022-2025 | |
| Boston Scientific Corporation | $108.08 | 2025 | Stingray, General - Vascular Access |
| E.R. Squibb & Sons, L.L.C. | $88.11 | 2024 | Eliquis |
| Kiniksa Pharmaceuticals International, Plc | $86.75 | 2024 | Arcalyst |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $76.97 | 2023-2024 | Injectafer |
| Kiniksa Pharmaceuticals, LTD. | $49.47 | 2023 | Arcalyst |
| Merck Sharp & Dohme LLC | $47.43 | 2024-2025 | Verquvo |
| Lantheus Medical Imaging, INC. | $31.24 | 2023 | Definity |
| Lexicon Pharmaceuticals, INC. | $24.06 | 2024 | |
| Shockwave Medical, INC | $23.17 | 2025 | |
| Asahi Intecc USA, INC. | $15.40 | 2025 | Asahi Coronary Wires |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ayedh Alamri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.